Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
(Accessed 2025) for general background and side effect incidence from Phase 3 trials
1 Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as non-alcoholic fatty liver disease (NAFLD), has become the most prevalent chronic liver condition worldwide, affecting approximately one-third to nearly 40% of the adult population globally, with projections indicating an increase to over 55% by 2040 ( (THR-) agonist, received approval from the FDA in 2024 for the treatment of adult patients with F2-F3 MASH ( Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained considerable attention in recent years as promising therapeutic agents for MASLD, particularly owing to their well-established efficacy in treating type 2 diabetes mellitus (T2DM) and obesity, conditions closely implicated to MASLD pathogenesis ( This review aims to systematically summarize the mechanistic insights and clinical advances of GLP-1with dual or triple receptor agonists in MASLD treatment, thereby promoting a more profound comprehension and facilitating their application in clinical practice (Figure 1)
:format(webp))
Eating enough (usually 500-750 calories below what you burn) actually helps you lose weight more sustainably
Ensuring world-class coverage for all TRICARE beneficiaries, regardless of age, remains at the heart of MOAAs mission
US$ 22.87
US$ 28.37
US$ 27.17
US$ 25.48
US$ 24.64
US$ 26.36
US$ 28.47
US$ 25.87
